AU2011256264B2 - Method for purifying a fused pyrrolocarbazole derivative - Google Patents

Method for purifying a fused pyrrolocarbazole derivative Download PDF

Info

Publication number
AU2011256264B2
AU2011256264B2 AU2011256264A AU2011256264A AU2011256264B2 AU 2011256264 B2 AU2011256264 B2 AU 2011256264B2 AU 2011256264 A AU2011256264 A AU 2011256264A AU 2011256264 A AU2011256264 A AU 2011256264A AU 2011256264 B2 AU2011256264 B2 AU 2011256264B2
Authority
AU
Australia
Prior art keywords
formula
compound
theta
degrees
acid complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011256264A
Other languages
English (en)
Other versions
AU2011256264A1 (en
Inventor
Shawn P. Allwein
Arnaud Grandeury
Guy Piacenza
Sebastien Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Sante SAS
Cephalon LLC
Original Assignee
Teva Sante SAS
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Sante SAS, Cephalon LLC filed Critical Teva Sante SAS
Publication of AU2011256264A1 publication Critical patent/AU2011256264A1/en
Assigned to CEPHALON, INC., TEVA SANTE reassignment CEPHALON, INC. Amend patent request/document other than specification (104) Assignors: CEPHALON FRANCE, CEPHALON, INC.
Application granted granted Critical
Publication of AU2011256264B2 publication Critical patent/AU2011256264B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2011256264A 2010-05-18 2011-05-17 Method for purifying a fused pyrrolocarbazole derivative Active AU2011256264B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34583110P 2010-05-18 2010-05-18
US61/345,831 2010-05-18
PCT/US2011/036814 WO2011146488A1 (en) 2010-05-18 2011-05-17 Method for purifying a fused pyrrolocarbazole derivative

Publications (2)

Publication Number Publication Date
AU2011256264A1 AU2011256264A1 (en) 2013-01-10
AU2011256264B2 true AU2011256264B2 (en) 2016-09-15

Family

ID=44168420

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011256264A Active AU2011256264B2 (en) 2010-05-18 2011-05-17 Method for purifying a fused pyrrolocarbazole derivative

Country Status (20)

Country Link
US (1) US8884014B2 (enExample)
EP (1) EP2571885B1 (enExample)
JP (2) JP5828594B2 (enExample)
KR (1) KR101815332B1 (enExample)
CN (1) CN102958934B (enExample)
AU (1) AU2011256264B2 (enExample)
BR (1) BR112012029374B1 (enExample)
CA (1) CA2799517C (enExample)
CL (1) CL2012003208A1 (enExample)
EA (1) EA021869B1 (enExample)
ES (1) ES2530015T3 (enExample)
IL (2) IL223016A0 (enExample)
MX (1) MX2012013304A (enExample)
MY (1) MY156830A (enExample)
NZ (1) NZ604135A (enExample)
PH (1) PH12012502250A1 (enExample)
SG (2) SG10201503541WA (enExample)
UA (1) UA108498C2 (enExample)
WO (1) WO2011146488A1 (enExample)
ZA (1) ZA201209305B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509282A (ja) 2008-11-19 2012-04-19 セファロン、インク. インダゾロ[5,4−a]ピロロ[3,4−c]カルバゾール化合物の新しい形態

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059795A1 (en) * 2008-11-19 2010-05-27 Cephalon, Inc. Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2220811T3 (es) * 2000-09-29 2004-12-16 Eli Lilly And Company Procedimiento y compuestos para el tratamiento de enfermedades proliferativas.
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
JP2006241579A (ja) 2005-03-07 2006-09-14 Nippon Paint Co Ltd 化成処理剤及び表面処理金属

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059795A1 (en) * 2008-11-19 2010-05-27 Cephalon, Inc. Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound

Also Published As

Publication number Publication date
MX2012013304A (es) 2013-04-03
US8884014B2 (en) 2014-11-11
BR112012029374B1 (pt) 2021-05-25
CL2012003208A1 (es) 2013-05-17
ZA201209305B (en) 2014-02-26
CN102958934B (zh) 2015-06-17
MY156830A (en) 2016-03-31
UA108498C2 (en) 2015-05-12
IL242221A0 (en) 2015-11-30
SG10201503541WA (en) 2015-06-29
CA2799517A1 (en) 2011-11-24
EP2571885A1 (en) 2013-03-27
IL242221B (en) 2018-06-28
CA2799517C (en) 2019-01-22
SG185645A1 (en) 2012-12-28
EA021869B1 (ru) 2015-09-30
AU2011256264A1 (en) 2013-01-10
WO2011146488A1 (en) 2011-11-24
JP2013526573A (ja) 2013-06-24
NZ604135A (en) 2015-02-27
EP2571885B1 (en) 2014-11-12
BR112012029374A2 (pt) 2016-07-26
PH12012502250A1 (en) 2013-02-04
CN102958934A (zh) 2013-03-06
HK1182100A1 (en) 2013-11-22
JP2016074668A (ja) 2016-05-12
JP5828594B2 (ja) 2015-12-09
ES2530015T3 (es) 2015-02-25
US20130123499A1 (en) 2013-05-16
KR20140095116A (ko) 2014-08-01
BR112012029374A8 (pt) 2017-12-26
EA201291269A1 (ru) 2013-05-30
IL223016A0 (en) 2013-02-03
KR101815332B1 (ko) 2018-01-04

Similar Documents

Publication Publication Date Title
US11168057B2 (en) Polymorphs and co-crystals of roxadustat
WO2009120746A2 (en) Crystalline forms of sitagliptin phosphate
HRP20030392A2 (en) Crystalline venlafaxine base and novel polymorphsof venlafaxine hydrochloride, processes for preparing thereof
WO2020207753A1 (en) Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate
WO2011021218A2 (en) Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
AU2011256264B2 (en) Method for purifying a fused pyrrolocarbazole derivative
EP3166942A1 (en) Process for prepararing apixaban
WO2014102834A2 (en) Process for lurasidone
HK1182100B (en) Method for purifying a fused pyrrolocarbazole derivative
JP2717995B2 (ja) 1,2,3−トリアゾールの製法
WO2016142173A1 (en) 4-(2-methyl-1h-imidazol-1-yl)-2,2-diphenylbutanenitrile solid form
JP7748370B2 (ja) トリアゾリンジオン付加体の製造方法
BR112012029363B1 (pt) Processo para preparar 1-alquil-3-difluorometil-5 -hidroxipirazóis
US20100179318A1 (en) Process to make lestaurtinib
CA3226626A1 (en) Crystal form of compound represented by formula i, and preparation therefor and application thereof
CN114790161A (zh) 4-甲氧基羰基乙基-3-甲基-2-吡咯醛的合成方法及其中间体
US7589194B2 (en) Crystalline k-252b, sodium salt, methanolate pentahydrate
TW202540077A (zh) 具有抗癌活性之mdm2-p53交互作用的異吲哚啉酮抑制劑的中間體的製造方法
WO2011114336A1 (en) Process for the isolation of ganciclovir intermediate
EP3999495A1 (en) Improved process for preparing ozanimod
US20080177063A1 (en) CRYSTALLINE K-252b, SODIUM SALT, HYDRATE
US20080171867A1 (en) CRYSTALLINE K-252a BIS(TETRAHYDROFURANATE)
WO2009014679A1 (en) Dolasetron trifluoroacetate, polymorphs of dolasetron trifluoroacetate and process for preparation thereof
WO2016021524A1 (ja) 光学活性2-メチルピペラジンの製造方法
WO2011017299A2 (en) PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)